Clinical Trial Update: Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated neoadjuvant chemoradiation therapy combined with immunotherapy for microsatellite-stable ultra-low rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Changhai Hospital | Conditions: Neoadjuvant Chemoradiation Therapy, Rectal Cancer | Phase 2, Phase 3 | Status: COMPLETED